• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Cancer Trial Success Just Shift Pfizer (PFE) Investment Narrative?

    Simply Wall St·11/03/2026 02:33:14
    Listen to the news
    • Pfizer reported several oncology updates, including positive Phase 3 topline data for ELREXFIO in relapsed or refractory multiple myeloma and an expanded U.S. FDA approval for TALZENNA plus XTANDI in earlier metastatic prostate cancer with homologous recombination repair gene mutations.
    • These cancer portfolio milestones, together with plans to submit ELREXFIO data to global regulators, draw attention to how Pfizer is trying to build non COVID revenue pillars while managing safety, real world adoption and regulatory execution across multiple tumor types.
    • We will examine how Pfizer's investment narrative is influenced by ELREXFIO's Phase 3 results and the new TALZENNA label expansion.

    Scan how Pfizer's oncology moves compare with other potential compounders across the sector by reviewing a curated list of 33 healthcare AI stocks.

    Pfizer Investment Narrative Recap

    To own Pfizer, you need to be comfortable with a business that is trying to replace falling COVID revenue with oncology, vaccines and future obesity drugs while holding margins together through roughly US$9.7b of planned cost savings by 2029. The Unified Patent Court ruling on the Enanta case removes a legal overhang around Paxlovid in key EU markets, but it does not change the broader COVID step down story.

    The key near term swing factor remains execution on launched and acquired products and whether they can offset guidance for COVID revenue to decline from about US$11b in 2024 to an expected US$4b in 2026. Main risks still sit with drug pricing pressure, pipeline disappointments and a high debt load rather than this specific legal decision.

    The ELREXFIO Phase 3 MagnetisMM-32 readout is the most relevant update if you are tracking catalysts around Pfizer right now. Positive progression free survival versus several active regimens in relapsed or refractory multiple myeloma speaks directly to the goal of building a larger oncology contribution as older products face loss of exclusivity and COVID sales fall.

    Operationally, ELREXFIO is already approved in more than 35 countries. Stronger data in earlier treatment lines can matter for physician adoption, reimbursement discussions and how investors think about durability of this revenue stream. It also links to Pfizer’s wider use of biomolecular AI and analytics to shorten clinical timelines and manage complex global submissions, which are practical execution levers behind the shift toward non COVID revenue pillars.

    How Pfizer’s Oncology News Feeds Into The Numbers

    For anyone tracking Pfizer, the oncology headlines land against a backdrop where analysts already assume the top line will shrink by 5.2% a year over the next three years, even as profitability is expected to improve. The working model is simple: a smaller revenue base, but a higher margin mix as COVID fades, oncology and other therapies scale, and cost cuts flow through the income statement.

    On current estimates, earnings today are about US$4.3b and the analyst consensus points to US$9.1b by 2029. That is roughly a 2.1x step up in profit, paired with an assumed expansion in net margin from 6.8% to 16.8% over the same rough timeframe. The oncology portfolio, including ELREXFIO and the broader Seagen assets, sits inside that margin story because higher value therapies can support richer profitability if pricing, access and uptake hold together.

    The price targets floating around the stock reflect these moving parts more than any one trial readout. The current consensus target of US$28.88 is only 2.6% above the recent share price of US$28.12, with a fairly wide spread between bullish and cautious views at US$35.75 and US$25.00. That narrow gap between price and target signals that, on average, analysts see Pfizer as roughly fairly priced given today’s information, including the assumption that oncology and obesity programs will help offset the guided COVID decline and loss of exclusivity headwinds.

    Underpinning those targets is a valuation bridge that asks investors to accept a different mix of revenue and earnings than the one Pfizer has today. To line up with consensus, you would need to be comfortable with Pfizer generating about US$54.3b of revenue and US$9.1b of earnings in 2029 and trading on a P/E of 22.5x, down from 36.9x but still above the current US pharmaceuticals group at 15.3x. The implied premium to the sector leans heavily on the belief that oncology, obesity and the acquired products pool can support better margin and earnings quality than a COVID heavy profile.

    Pfizer's narrative projects US$54.3b revenue and US$9.1b earnings by 2029. This is built on a 5.2% yearly revenue decline and an earnings increase of about 2.1x from US$4.3b today.

    Uncover why Pfizer's fair value indicates a 6% potential downside to its current price that leaves little room for error.

    NYSE:PFE 1-Year Stock Price Chart
    NYSE:PFE 1-Year Stock Price Chart

    Exploring Other Perspectives

    For a different lens, focus on obesity rather than oncology. The most optimistic Pfizer analysts were modelling about US$56.5b of revenue and US$12.6b of earnings by 2029, compared with the baseline US$54.3b and US$9.1b. Those forecasts were set before the ELREXFIO and TALZENNA news, so opinions could shift. Use this spread as a prompt to compare several views, rather than follow just one.

    Explore 10 other Pfizer fair value estimates, including one that suggests as much as 114% upside from the current price!

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Pfizer?

    If you want to stress test your view on Pfizer against other opportunities, the Simply Wall St Screener can help you quickly line up stocks with very different profiles and risk levels.